Compare FOXF & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | CTMX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.2M | 596.2M |
| IPO Year | 2013 | 2015 |
| Metric | FOXF | CTMX |
|---|---|---|
| Price | $17.58 | $5.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $30.67 | $8.86 |
| AVG Volume (30 Days) | 571.4K | ★ 2.9M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | $138,103,000.00 |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | 5.27 | ★ 36.45 |
| 52 Week Low | $13.08 | $0.40 |
| 52 Week High | $31.18 | $6.35 |
| Indicator | FOXF | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 50.09 |
| Support Level | $17.50 | $5.10 |
| Resistance Level | $17.98 | $6.25 |
| Average True Range (ATR) | 1.09 | 0.33 |
| MACD | -0.26 | -0.06 |
| Stochastic Oscillator | 37.67 | 33.18 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.